Expanding Cancer Susceptibility Gene Testing: Exploring Evidence Gaps
The PHG Foundation hosted a seminar featuring Professor Clare Turnbull on the shift from reactive to proactive testing of cancer susceptibility genes (CSGs). Traditionally, genetic testing was reserved for individuals with strong family histories or specific clinical presentations. However, current trends involve proactive identification of germline pathogenic variants through routine genomic analyses in cancer patients, direct-to-consumer services, and population-wide screening programs. This expansion means more individuals are identified as carriers without prior suspicion, raising critical questions about disease penetrance and intervention efficacy. Professor Turnbull emphasized the need to robustly evaluate evidence to ensure that assigning lifelong carrier status provides net benefit over harm. The discussion highlighted the importance of validating clinical utility for early detection and prevention strategies. As healthcare systems like the NHS scale up high-throughput genomic testing pathways, particularly for BRCA genes, understanding these evidence gaps is essential for safe and effective public health implementation. The event aimed to bridge academic research and public health practice regarding genomic risk stratification.
Wire timeline
Expanding Cancer Susceptibility Gene Testing: Exploring Evidence Gaps
The PHG Foundation hosted a seminar featuring Professor Clare Turnbull on the shift from reactive to proactive testing of cancer susceptibility genes (CSGs). Traditionally, genetic testing was reserved for individuals with strong family histories or specific clinical presentations. However, current trends involve proactive identification of germline pathogenic variants through routine genomic analyses in cancer patients, direct-to-consumer services, and population-wide screening programs. This expansion means more individuals are identified as carriers without prior suspicion, raising critical questions about disease penetrance and intervention efficacy. Professor Turnbull emphasized the need to robustly evaluate evidence to ensure that assigning lifelong carrier status provides net benefit over harm. The discussion highlighted the importance of validating clinical utility for early detection and prevention strategies. As healthcare systems like the NHS scale up high-throughput genomic testing pathways, particularly for BRCA genes, understanding these evidence gaps is essential for safe and effective public health implementation. The event aimed to bridge academic research and public health practice regarding genomic risk stratification.
PHG Foundation